Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet, vol
Those are literature ranges across studies rather than a single trial result
'fb_in_app_browser_popup } 'in_app_browser_popup } word('read_more') word('consent_desc') word('read_more') setting } getChildVariationShorthand(childProduct } x selectedChildProduct } Not enough stock
Check the Novo Nordisk website or ask your doctor about enrolling
The Phase 2 trial documented these side effects across all dose groups, and the data tells a clear story: most symptoms are gastrointestinal, most are mild to moderate, and most improve as the body adapts
Join us to discover the exclusive insights and science behind medication-altered taste perception and the massive market its creating